Angiotensin II (3-8), human

Cat. No.: HY-P1515: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Angiotensin II (3-8), human Chemical Structure

CAS No. : 12676-15-2

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Angiotensin II (3-8), human:

Angiotensin II (3-8), human TFA

Other Forms of Angiotensin II (3-8), human:

Angiotensin II (3-8), human TFA In-stock

2 Publications Citing Use of MCE Angiotensin II (3-8), human

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Angiotensin Receptor Isoform Specific Products:

View All Isoforms

AT1 Receptor AT2 Receptor

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description	Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.
IC₅₀ & Target	Angiotensin AT₁ receptor^[1]
In Vivo	Human Angiotensin II (3-8) causes endothelium-dependent renal cortical vasodilatation, in anaesthetized rats. At doses up to 125 pmol/kg, human Angiotensin II (3-8) is without any cardiovascular effects, but with doses of 1.25 and 12.5 nmol/kg there are dose-dependent increases in mean arterial blood pressure and reductions in renal and mesenteric flows and vascular conductances^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	774.91
Formula	C₄₀H₅₄N₈O₈
CAS No.	12676-15-2
Sequence	Val-Tyr-Ile-His-Pro-Phe
Sequence Shortening	VYIHPF
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (281 KB) Handling Instructions (2659 KB)
References	[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62. [Content Brief]

Animal Administration
^[1]

Rats^[1]
Male Long Evans rats (350-450 g) (n=7) are given increasing bolus doses of AII (1.25, 12.5 and 125 pmol/kg) or human Angiotensin II (3-8) (0.125, 1.25 and 12.5 nmol/kg) in random order, in the morning or afternoon of the same experimental day. Injections are separated by at least 20 min to allow variables to return to baseline^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Gardiner SM, et al. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol. 1993 Sep;110(1):159-62. [Content Brief]